Non-HDL Cholesterol and Type 2 Diabetes Mellitus

*S Zabeen¹, MR Rahman², TG Mustafa³, NH Eusufzai⁴, S Shermin⁵

¹Dr. Shahana Zabeen, Dept. of Biochemistry, AKMMC.
²Dr. Md. Rezwanur Rahman, Dept. of Biochemistry, Delta Medical College. Dhaka.
³Dr. Tarek Golam Mustafa. MD (Resident) Dept. of Pharmacology. BSMMU. Dhaka.
⁴Dr. Nazmul Haque Eusufzai. Senior Medical Officer, OPD. BIRDEM.Dhaka.
⁵Dr. Shahana Shermin. Senior Medical Officer, Dept. of Gynae & Obs. BIRDEM, Dhaka.

* Corresponding Author

ABSTRACT

Non-HDL cholesterol (non HDL-C) is such a marker that is obtained by subtracting the level of HDL cholesterol from total cholesterol⁵. The resulting value measures not only LDL cholesterol but also other apoprotein-B containing particles, such as VLDL, IDL and chylomicron remnants³. Although apo-B can be assessed directly but its measurement is not widely available in commercial laboratories¹. But measurement of non HDL-C is more practical, simple, reliable, and inexpensive and is accepted as a surrogate marker in routine clinical practice⁵. Unlike LDL cholesterol, which can be incorrectly calculated in presence of postprandial hypertriglyceridemia, (and require fasting sample) non HDL-C is reliable when measure in non-fasting state⁷.

Non-HDL cholesterol reflects total cholesterol minus HDL cholesterol and encompasses all cholesterol present in potentially atherogenic lipoprotein particles. It has been recently suggested that Non-HDL cholesterol might be a useful marker and a better predictor of atherosclerosis in type 2 diabetic subjects. The study was designed to explore the role of non-HDL cholesterol in diabetic population. It was a case-control study. 150 subjects irrespective of sex were selected. Of them 103 were diabetic and 47 were non-diabetic. The lipid profile including total cholesterol, TG and HDL-C were measured following standard method & procedure. LDL-C was calculated using Friedwald’s formula. TG concentration of >400 mg/dl were excluded from the study. Non HDL-C is calculated by subtracting the level of HDL cholesterol from total cholesterol. Unpaired t test and chi square test were done to find out the level of significance. Non-HDL cholesterol was compared between the study groups and significant differences were observed (p value <0.001). Non-HDL cholesterol is elevated in type 2 diabetes mellitus and therefore should perform as a routine assessment in all diabetic subjects.

Key word: Non-HDL-C (Non-HDL cholesterol), TGRLP (Triglyceride rich lipoproteins), Type 2 Diabetes.

Introduction

A standard lipid profile consists of total cholesterol (TC), HDL-C, LDL-C and triglycerides (TG)¹. Although levels of LDL cholesterol are the primary focus of dyslipidaemia screening, in diabetic people but relying on LDL targets alone can be misleading in such patients since they produce highly atherogenic VLDL and IDL lipoproteins as well as small dense atherogenic LDL particles, in spite of normal LDL values². It is now clear that LDL is not the only atherogenic lipoprotein but apoprotein-B containing particles, such as VLDL, IDL and chylomicron remnants are also potentially atherogenic³. So, researchers have looked at other measurements that can help them to identify the diabetic people who are at increased risk of atherosclerosis⁴.
As LDL is the primary carrier of cholesterol in plasma, VLDL and IDL are the main carriers of TG\(^7\). These TG rich lipoproteins (TGRLPs) also carry cholesterol\(^8\). In the presence of hypertriglyceridemia, TGRLPs may be partly depleted of their TG content and become enriched with cholesterol from LDL. The modified remnant lipoproteins that result are believed to be highly atherogenic because of their small size, high cholesterol content and increase residence time in plasma\(^9\). They are able to deliver more cholesterol to macrophages than LDL particles because they can penetrate the arterial wall with ease, be taken up directly by macrophages, and participate in foam cell formation, thus initiating the lipid laden plaque\(^10\).

At the same time, LDL exchanges core lipids with VLDL to become TG rich and undergoes lipolysis, resulting in a smaller and denser LDL particle\(^11\). These compacted lipid depleted LDL particles are more atherogenic because they are more easily oxidized and readily penetrate the artery wall. However, even though small dense LDL particles are greater in number and atherogenesity than normal-sized LDL, LDL cholesterol level appears normal rather than high on standard measurements because small dense particles are lipid poor\(^12\).

Therefore, the measurement of LDL cholesterol alone may not always provide sufficient measure of atherogenic risk in subjects with type 2 diabetes mellitus. As the measurement of non HDL-C is simple and can be calculated after a standard cholesterol test, so, measuring non-HDL cholesterol can be useful in assessing their risk and guiding their treatment strategy\(^13\). Target goals for LDL and non HDL-C in patients with diabetes are <100 and <130 mg/dl\(^7\).

**Method**

It was a case control study carried out in the Department of Biochemistry, Anwer khan Modern Medical College (AKMMC). One hundred and fifty patients (150) irrespective of sex were selected purposively from OPD, BIRDEM and Anwer khan Modern Medical College Hospital (AKMMCH). Of them 103 were diagnosed type 2 DM taken as case and 47 were non-diabetic were control. The lipid profile including total cholesterol, TG and HDL-C were measured following standard method & procedure. LDL-C was calculated using Friedwald’s formula. TG concentration of >400 mg/dl were excluded from the study. Non HDL-C is calculated by subtracting the level of HDL cholesterol from total cholesterol. Relevant statistical tests were done in SPSS 12.0 version (p value <0.05 was taken as lowest level of significance).

**Results**

Table 1 show the distribution and comparison of age and sex of the study subjects out of 103 diabetic subjects number of male subjects was 70 and that of female was 33. On the other hand 26 were male and 21 were female in total 47 non diabetic subjects. Mean age of the diabetic and non diabetic subjects were 46.53 ± 5.43 years with range of 39-62 years and 47.38 ± 7.61 years with range of 32-62 respectively. There was no statistically significant difference regarding age and sex between the groups (p > 0.05).

Table 1: Distribution & comparison of age & sex of the study subjects

<table>
<thead>
<tr>
<th>Group</th>
<th>Sex</th>
<th>t</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diabetic</td>
<td>70</td>
<td>33</td>
<td>46.53 ± 5.43 (Range 39-62)</td>
</tr>
<tr>
<td>Non-diabetic</td>
<td>26</td>
<td>21</td>
<td>47.38 ± 7.61 (Range 32-62)</td>
</tr>
</tbody>
</table>

**Table II:** Distribution & comparison of lipid profile between diabetic & non diabetic subjects

<table>
<thead>
<tr>
<th>Component</th>
<th>Diabetic (n=103)</th>
<th>Non diabetic (n=47)</th>
<th>t-value</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>TC (Mean±SD)</td>
<td>219.78 ± 41.74 (102-319)</td>
<td>178.38 ± 38.24 (99-262)</td>
<td>5.78</td>
<td>0.000</td>
</tr>
<tr>
<td>TG (Mean±SD)</td>
<td>265.53 ± 67.58 (120-400)</td>
<td>165.74 ± 69.85 (75-323)</td>
<td>8.30</td>
<td>0.000</td>
</tr>
<tr>
<td>HDL-C (Mean±SD)</td>
<td>38.23 ± 7.56 (26-206)</td>
<td>36 ± 8.64 (18-58)</td>
<td>1.53</td>
<td>0.131</td>
</tr>
<tr>
<td>LDL-C (Mean±SD)</td>
<td>129.37 ± 39.22 (51-179)</td>
<td>108.89 ± 31.71 (51-179)</td>
<td>3.14</td>
<td>0.002</td>
</tr>
</tbody>
</table>
profile, non HDL-C appears to be the parameter correlating best with apo-B the most atherogenic lipoprotein.

As people with type 2 diabetes often have elevated triglyceride level but relatively normal LDL-C value, so measuring their non HDL-C can be useful in assessing their risk of atherosclerosis and guiding their treatment. One advantage of factoring in non HDL-C is that it requires no additional testing; it simply can be calculated after a standard cholesterol test.

**Conclusion**

Non-HDL cholesterol can be useful in assessing the risk of atherosclerosis in type 2 DM therefore it should be included in lipid profile for assessing their risk and guiding treatment.

**References**


---

**Table III: Distribution & comparison of non HDL-Cholesterol between diabetic & non diabetic subjects**

<table>
<thead>
<tr>
<th>Grouping</th>
<th>Non HDL-C in mg/dl (Mean±SD)</th>
<th>t-value</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diabetic (n=103)</td>
<td>181 ± 40.11 (71-276)</td>
<td>5.73</td>
<td>0.000</td>
</tr>
<tr>
<td>Non diabetic (n=47)</td>
<td>142.47 ± 36.27 (68-219)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Table III shows mean non HDL-C (in mg/dl) in case and control which reveals significantly very high difference between the groups [181 ± 40.11 (range 71-276) vs. 142.47 ± 36.27 (range 68-219); p <0.001].

**Discussion**

In this case control study our attempt was to explore the role of non HDL-C in diabetic population. Our study revealed that non HDL-C is significantly higher in diabetic subjects than non diabetic subjects. Our finding is similar to the findings of Abbasi et al 2007, Pinto et al 2007 and Peters AL 2008. They suggests that though the LDL, the main cholesterol bearing lipoprotein is major determinant of atherosclerosis in patients with diabetes but elevated VLDL is also associated with increase in prothrombotic and procoagulant factors and inclusion of VLDL is easily possible by determining non HDL-C.

The adult treatment panel III of National Cholesterol Education Program (NCEP) emphasizes the need of for optimization of LDL cholesterol levels, but it has been recently recommended that non-HDL cholesterol may be a better predictor of atherosclerosis in Type 2 DM. NCEP also recognized the significance of non-HDL cholesterol in diabetes and considered it to be a secondary therapeutic target; nevertheless, LDL- cholesterol is defined as the main therapeutic target in the management of diabetic dyslipidaemia.

In systolic hypertension elderly program (SHEP) non HDL-C is elevated in both diabetes and hypertensive individuals. Our data was in agreement with this study also. The Strong Heart Study determines whether non HDL-C is a predictor of CVD in patients with diabetes. This study suggests that non HDL-C index may be particularly useful in predicting CVD risk in patients with diabetes. Because diabetic patients are high risk for CVD morbidity and mortality, adequate risk assessment and management is imperative. Within the realms of standard lipid groupings, non HDL-C appears to be the parameter correlating best with apo-B the most atherogenic lipoprotein.


